Cargando…

Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors

Histone acetylation is a posttranslational modification that plays a role in regulating gene expression. More recently, other nonhistone proteins have been identified to be acetylated which can regulate their function, stability, localization, or interaction with other molecules. Modulating acetylat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miller, Claudia P., Singh, Melissa M., Rivera-Del Valle, Nilsa, Manton, Christa A., Chandra, Joya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3134392/ https://www.ncbi.nlm.nih.gov/pubmed/21765634 http://dx.doi.org/10.1155/2011/514261

Ejemplares similares

Histone deacetylase inhibitors as novel anticancer therapeutics
por: Walkinshaw, D.R., et al.
Publicado: (2008)

Histone Deacetylase Inhibitors as Anticancer Drugs
por: Eckschlager, Tomas, et al.
Publicado: (2017)

PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells
por: Rivera-Del Valle, Nilsa, et al.
Publicado: (2010)

Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
por: Verza, Flávia Alves, et al.
Publicado: (2020)

Antitheilerial Activity of the Anticancer Histone Deacetylase Inhibitors
por: Barman, Madhumanti, et al.
Publicado: (2021)

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
por: Ververis, Katherine, et al.
Publicado: (2013)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies
por: Ellis, Leigh, et al.
Publicado: (2010)

Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy
por: Singh, Amit Kumar, et al.
Publicado: (2018)

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
por: Mottamal, Madhusoodanan, et al.
Publicado: (2015)

NBM-HD-1: A Novel Histone Deacetylase Inhibitor with Anticancer Activity
por: Huang, Wei-Jan, et al.
Publicado: (2012)

Synergistic Anticancer Effect of Glycolysis and Histone Deacetylases Inhibitors in a Glioblastoma Model
por: Pająk, Beata, et al.
Publicado: (2021)

Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo
por: Manton, Christa A., et al.
Publicado: (2016)

Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics
por: Chhabra, Saurabh
Publicado: (2017)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Anticancer effect of histone deacetylase inhibitor scriptaid as a single agent for hepatocellular carcinoma
por: Liu, Linlin, et al.
Publicado: (2018)

Multitarget Anticancer Agents Based on Histone Deacetylase and Protein Kinase CK2 Inhibitors
por: Martínez, Regina, et al.
Publicado: (2020)

Enhanced efficacy of histone deacetylase inhibitor combined with bromodomain inhibitor in glioblastoma
por: Meng, Wei, et al.
Publicado: (2018)

Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors
por: Han, Yu, et al.
Publicado: (2022)

A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma
por: Selim, Omar, et al.
Publicado: (2023)

The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
por: Cao, Fangyuan, et al.
Publicado: (2018)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors
por: Sonnemann, J, et al.
Publicado: (2014)

Improved Anticancer Activities of a New Pentafluorothio-Substituted Vorinostat-Type Histone Deacetylase Inhibitor
por: Goehringer, Nils, et al.
Publicado: (2021)

Histone Deacetylases in the Inflamed Intestinal Epithelium—Promises of New Therapeutic Strategies
por: Gerbeth, Lorenz, et al.
Publicado: (2021)

PB1856: DEMETHYLATING AGENTS AND HISTONE DEACETYLASE INHIBITORS AS NEW THERAPEUTIC STRATEGIES IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Jorge #, J., et al.
Publicado: (2022)

Histone Deacetylase Inhibitors: The Epigenetic Therapeutics That Repress Hypoxia-Inducible Factors
por: Chen, Shuyang, et al.
Publicado: (2011)

Therapeutic effects of histone deacetylase inhibitors in a murine asthma model
por: Ren, Yuan, et al.
Publicado: (2016)

Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma
por: Psilopatis, Iason, et al.
Publicado: (2021)

Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas
por: MANTA, ASPASIA, et al.
Publicado: (2023)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Acetylation and Histone Deacetylase Inhibitors in Cancer
por: Kortenhorst, Madeleine S. Q., et al.
Publicado: (2006)

The application of histone deacetylases inhibitors in glioblastoma
por: Chen, Rui, et al.
Publicado: (2020)

Histone Deacetylases and Their Inhibitors in Cancer Epigenetics
por: Hassell, Kelly N.
Publicado: (2019)

The synergistic anticancer effect of the bromodomain inhibitor OTX015 and histone deacetylase 6 inhibitor WT-161 in osteosarcoma
por: Yu, Bo, et al.
Publicado: (2022)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

Taking Advantage of the Selectivity of Histone Deacetylases and Phosphodiesterase Inhibitors to Design Better Therapeutic Strategies to Treat Alzheimer’s Disease
por: Cuadrado-Tejedor, Mar, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_n5r86e3f3lj77mtkbee2rf37m2